Abstract:Objective To observe the effect of vinpocetine combined with argatroban on vertebrobasilar insufficiency vertigo (VBIV) and its influences on inflammatory factors. Methods A total of 100 VBIV inpatients admitted to the First Affiliated Hospital of Hebei North University from March 2018 to January 2019 were randomly divided into treatment group and control group (n=50, each). Based on the routine treatment in both groups, vinpocetine was given in control group, and vinpocetine combined with argatroban was used in treatment group. After a 10-day treatment course, transcranial doppler (TCD) was used to determine the changes of blood flow velocity of bilateral vertebral artery and basilar artery, ELISA was used to detect the levels of C-reactive protein (CRP) and interleukin-6 (IL-6) before and after treatment, and radioimmunoassay was used to measure the changes of endothelin-1 (ET-1), calcitonin gene-related peptide (CGRP). Results The total effective rate in treatment group was significantly higher than that in control group (96.0% vs 76.0%, P<0.05). The blood flow velocity of the bilateral vertebral artery and basilar artery was higher in treatment group than that in control group (P<0.05). Compared with control group, the levels of IL-6, CRP and ET-1 decreased, and CGRP level increased in treatment group (P<0.05). Conclusion Vinpocetine combined with argatroban can improve the blood flow velocity of vertebrobasilar artery, and reduce the levels of serum inflammatory factors and vascular endothelial cells injury in VBIV patients.